|Cancer Stem Cell News 6.34 August 30, 2017
Researchers showed that the growth of glioblastoma clones in vivo is consistent with a remarkably neutral process involving a conserved proliferative hierarchy rooted in glioblastoma stem cells. [Nature]
Using a connectivity map, the authors identified prostaglandin E1 as a small molecule that partly elicited the gene expression changes in leukemic stem cells caused by Tcf1/Lef1 deficiency. [Cell Stem Cell]
Effective targeting of CSCs requires neutralization of self-renewal and chemoresistance, but these phenotypes are often regulated by distinct molecular mechanisms. Investigators report the ability to target both of these phenotypes via CD55, an intrinsic cell surface complement inhibitor, which was identified in a comparative analysis between CSCs and non-CSCs in endometrioid cancer models. [J Exp Med]
Scientists studied the ability of polymeric micelles cooperatively loading the cytotoxic drug epirubicin and the CSC inhibitor staurosporine to treat breast tumors, particularly when tumors relapsed after chemotherapy. [J Control Release]
The authors utilized the EGFRviii mutation, which frequently occurs in brain cancers, to establish another CNSC line, and characterized its stemness under spheroid culture. [Mol Cancer]
Researchers established one epithelial and two mesenchymal cell lines from ascites of a bladder cancer patient. Analyses of these cell lines demonstrated that the epithelial cells with surface expression of PD-L1, E-cadherin, CD24, and VEGFR2 rapidly formed tumors outside the primary tumor microenvironment in nude mice, exhibited signatures of immune evasion, increased stemness, increased calcium signaling, transformation, and novel E-cadherin–RalBP1 interaction. [Sci Rep]
Scientists established a primary lung cell culture from a patient in a clinically rare and unique situation of primary resistant disease. This culture consisted of two biologically profoundly distinct adenocarcinoma cell subpopulations, which differed phenotypically and genotypically. [Sci Rep]
Researchers found that miR-221/222 were overexpressed in highly aggressive breast cancer MDA-MB-231 cells, that are enriched in markers for epithelial-mesenchymal transition and breast cancer stem cells, than in MCF-7 cells. [Chem Biol Interact]
Through real-time PCR, western blotting, luciferase assays, RNA immunoprecipitation, and in vitro and in vivo assays, investigators demonstrated that miR-217 expression was markedly increased in hepatocellular carcinoma tissues and cells. [Oncol Rep]
The authors present evidence for the existence of a unique small population of CD44v3highALDHhigh-expressing CSCs in head and neck squamous cell carcinoma. They focused on the role of hyaluronan/CD44-induced oncogenic signaling and histone methyltransferase, DOT1L activities in regulating histone modifications and miRNA activation. [Int J Mol Sci]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
Bristol-Myers Squibb Company and Daiichi Sankyo Company, Limited announced a collaborative clinical trial to evaluate the combination of Bristol-Myers Squibb’s immunotherapy Opdivo and Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 in HER2-expressing metastatic breast and urothelial cancers. [Bristol-Myers Squibb Company]
BloodCenter of Wisconsin’s Diagnostic Laboratories is the first to offer testing using Abbott Laboratories’ RealTime IDH2 assay that identifies specific gene mutations in patients with acute myeloid leukemia. [BloodCenter of Wisconsin]
China is tightening the screws on internet access, again. The latest crackdown—an evolving effort to ban virtual private networks not under government control—could seriously erode scientists’ ability to stay connected with peers abroad. [ScienceInsider]
In the last few days alone, the FDA has taken steps in Florida and California to address a number of especially troubling products being marketed. But unfortunately, these are examples of a larger pool of actors who claim that their unproven and unsafe products will address a serious disease, but instead put patients at significant risk. [U.S. Food and Drug Administration]
The FDA posted a warning letter issued to US Stem Cell Clinic of Sunrise, Florida, and its Chief Scientific Officer Kristin Comella for marketing stem cell products without FDA approval and for significant deviations from current good manufacturing practice requirements, including some that could impact the sterility of their products, putting patients at risk. [U.S. Food and Drug Administration]
NEW American Society for Cell Biology (ASCB)-European Molecular Biology Organization (EMBO) 2017 Meeting
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.